Filing Summary
Registrant: NLS Pharmaceutics Ltd. The provided request identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd.; this discrepancy should be verified.
Filing: Form 6-K for the month of June 2022, filed June 1, 2022. The registrant is a foreign private issuer reporting under Form 20-F.
Business Context and Reporting Period
The filing reports results of the registrant’s ordinary shareholders’ meeting and a Nasdaq listing-compliance update. It does not provide operating or financial results for the period.
Key Financial Metrics
- Revenue, net income, margins, operating cash flow, capital expenditures, debt, cash, and liquidity: the filing text does not provide clear values.
- No balance-sheet, income-statement, or cash-flow information is included.
Material Changes and Corporate Actions
- At the ordinary shareholders’ meeting convened on May 31, 2022, a quorum was present and shareholders approved all agenda items as originally proposed.
- On May 27, 2022, Nasdaq granted the registrant an extension until September 27, 2022, to regain compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement for continued listing.
- The filing was incorporated by reference into the registrant’s Form F-3 registration statement, File No. 333-262489, to the extent not superseded by subsequent filings.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no revenue or earnings guidance.
- The Nasdaq extension indicates an ongoing minimum-stockholders’ equity compliance risk. Continued listing status depends on regaining compliance by September 27, 2022, subject to applicable Nasdaq procedures.
- No additional contingencies, liquidity plans, or management outlook are disclosed.
Investor Verification Items
- Verify the registrant’s identity because the request names Newcelx Ltd., while the filing names NLS Pharmaceutics Ltd.
- Review subsequent SEC filings to determine whether the minimum stockholders’ equity deficiency was cured by the September 27, 2022 deadline.
- Review the meeting materials or subsequent disclosures to confirm the specific agenda items approved by shareholders.
- Consult the company’s financial statements and later filings for cash, debt, liquidity, operating results, and any financing undertaken to address the Nasdaq deficiency.